Why Spravato Triggers Anxiety in Some Patients
Spravato (esketamine) triggers anxiety in some patients as a direct pharmacological effect of its action as an NMDA receptor antagonist, producing dissociative symptoms and perceptual disturbances that patients may experience as anxiety, particularly during the acute post-administration period. 1
Mechanism of Anxiety Induction
The FDA label explicitly lists anxiety as a known adverse effect of esketamine, occurring alongside other dissociative symptoms including perception disturbances, dizziness, vertigo, and feelings of being "spaced out," "floating," or "detached" 1. These symptoms stem from esketamine's mechanism as a non-selective, non-competitive NMDA receptor antagonist, though the precise pathway by which this produces anxiety remains incompletely understood 1.
Acute Dissociative Phenomena
The anxiety experienced with Spravato is intimately linked to dissociative episodes. In abuse potential studies, esketamine at therapeutic doses (84 mg) and supratherapeutic doses (112 mg) produced significantly elevated scores for "Hallucinating," "Floating," "Detached," and "Spaced Out" compared to placebo 1. For many patients, these perceptual alterations are inherently anxiety-provoking, particularly when unexpected or poorly understood.
Recent case reports demonstrate that dissociative symptoms can manifest as acute anxiety attacks. One notable case described a patient who experienced dissociative episodes lasting 40 minutes that caused significant anxiety and confusion 2. More concerning, another case documented delayed spontaneous dissociative symptoms occurring between treatment sessions, often accompanied by anxiety, suggesting esketamine may create a "pattern" for dissociative experiences that heightens patients' awareness of dissociation during other anxiety-provoking situations 3.
Clinical Context and Time Course
The anxiety triggered by Spravato is typically transient, dose-dependent, and most pronounced during the 2-hour post-administration monitoring period 4, 5. This is why the FDA mandates 2-hour supervised monitoring after each dose—to observe patients until sedation, dissociation, and anxiety effects resolve 1.
The majority of these adverse effects are:
- Mild to moderate in severity
- Transient (resolving within hours)
- Attenuate with subsequent treatments as patients become familiar with the experience 4
However, the 2022 VA/DoD guidelines acknowledge that esketamine carries "risks for adverse effects," which must be balanced against benefits, particularly given limited long-term safety data 6.
Risk Factors and Patient Selection
Individuals with pre-existing anxiety disorders or history of substance use disorder may be at heightened risk for anxiety reactions. The FDA label specifically warns that "individuals with a history of drug abuse or dependence may be at greater risk" for problematic responses, including anxiety and dysphoria 1.
The abuse potential study revealed that esketamine produces anxiety, dysphoria, disorientation, and hallucinations as part of its psychoactive profile 1. Patients unfamiliar with dissociative experiences or those with heightened anxiety sensitivity may interpret these effects as threatening, amplifying the anxiety response.
Management Strategies
Prevention
- Comprehensive patient education about expected dissociative and perceptual effects before first administration
- Setting appropriate expectations that unusual sensations are temporary and part of the medication's known effects
- Careful screening to identify patients with anxiety disorders who may require additional support 4
Acute Management During Sessions
Non-pharmacologic interventions are first-line for managing anxiety during dissociative episodes:
- Music therapy: Having patients listen to music of their choice during and immediately after administration significantly reduces anxiety and confusion associated with dissociation 2
- Verbal reassurance from healthcare staff throughout the monitoring period
- Supportive presence in a calm, controlled environment 4, 2
Pharmacologic Considerations
For severe or clinically significant anxiety that persists despite supportive measures, "judicious use of adjunctive medications" may be necessary 4. However, the evidence does not specify which agents are most appropriate, and this should be individualized based on the severity and nature of symptoms.
Dose Adjustment
Approximately 19% of patients require dose reduction from 84 mg to 56 mg twice weekly, often due to tolerability concerns including anxiety 1. If anxiety is severe or persistent, consider dose reduction before discontinuation.
Important Caveats
Distinguish between medication-induced anxiety and underlying depression with anxiety symptoms: Esketamine has demonstrated efficacy in reducing anxiety symptoms in patients with MDD and comorbid anxiety 7, 8, so paradoxically, while it may acutely trigger anxiety during administration, it can reduce baseline anxiety over time.
Monitor for delayed dissociative phenomena: Unlike typical acute effects, some patients experience spontaneous dissociative episodes with anxiety between treatment sessions 3. This is rare but requires clinical awareness.
The 2-hour monitoring requirement exists specifically because these effects are predictable and time-limited 1. Anxiety occurring outside this window warrants different diagnostic consideration.
Esketamine requires REMS certification precisely because of these neuropsychiatric effects, ensuring administration occurs only in supervised settings with trained providers 1.
The anxiety triggered by Spravato represents a direct pharmacological consequence of NMDA receptor antagonism producing dissociative states that patients may experience as anxiety-provoking, particularly during initial treatments before habituation occurs.